Navigation Links
Mylan Reports Third Quarter 2013 Adjusted Diluted EPS of $0.82
Date:10/31/2013

in third party net revenues of approximately 10%. This increase was principally the result of a double-digit increase in revenues in France and Italy as a result of new product revenue and favorable volumes. Partially offsetting these increases was unfavorable pricing in a number of European markets in which Mylan operates as a result of government imposed pricing reductions and competitive market conditions.

Third party net revenues from Asia Pacific were $993.1 million for the nine months ended September 30, 2013, compared to $945.4 million for the comparable prior year period, an increase of $47.8 million, or 5.1%. Foreign currency translation had a negative impact on sales, principally reflecting the significant strengthening of the U.S. Dollar versus the Indian Rupee, Australian Dollar and Japanese Yen. Excluding the effect of foreign currency translation, calculated as described above, third party net revenues would have increased by approximately $149 million, or 16%. This increase is primarily driven by higher revenues from Mylan India, as a result of increased sales of antiretroviral finished dosage form generic products, which are used in the treatment of HIV/AIDS, and an increase in sales of active pharmaceutical ingredients (API). In addition, local currency revenues increased in Japan due to higher volumes and new product introductions.

For the nine months ended September 30, 2013, Mylan's Specialty segment reported third party net sales of $805.7 million, an increase of $126.2 million, or 18.6%, from the comparable prior year period of $679.4 million. The most significant contributor to Specialty segment revenues continues to be the EPIPEN® Auto-Injector, sales of which increased as a result of favorable pricing and volume. The EPIPEN® Auto-Injector is the number one epinephrine auto-injector for the treatment of severe allergic reactions. In addition, Perforomist® Inhalation Solution sales increased by double d
'/>"/>

SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine technology :

1. Mylan Supports Generic Drug Industrys Call on FDA to Uphold Consistent, Proven International Standard for Biosimilar Naming
2. Mylan to Speak at the Morgan Stanley Global Healthcare Unplugged Conference
3. Mylan to Speak at the Bank of America Merrill Lynch Global Healthcare Conference
4. Mylan Announces Completion of Transdermal Patch Facility Expansion Project in St. Albans, Vt.
5. Mylan Acquisition of Agila Receives Approval from Indias Foreign Investment Promotion Board and Cabinet Committee on Economic Affairs
6. Mylan Confirms Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
7. Mylan Reports a 13% Increase in Second Quarter 2013 Adjusted Diluted EPS to $0.68
8. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
9. Mylan to Host Investor Day on Aug. 1, 2013 in New York City
10. Roger Graham Named President of Mylan Specialty
11. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Akcea Therapeutics, a wholly-owned subsidiary of ... today that the U.S. Food and Drug Administration ... Rx ) for the treatment of patients with ... genetic disease characterized by extremely high triglyceride levels ... study published in the NEJM in December 2014, ...
(Date:7/6/2015)... SHENZHEN, China , July 6, 2015 /PRNewswire/ -- China ... or the "Company"), a leading retail drugstore chain in ... of directly operated stores, today announced that its board ... dated July 6, 2015, from Simin Zhang , ... and China Neptunus Drugstore Holding Ltd., an investment vehicle ...
(Date:7/4/2015)... 2015 De toevoeging ... voor patiënten met niet-resectabele uitgezaaide colorectale kanker ... overleving in dat orgaan. Bij ... die alleen binnen de lever is uitgezaaid,werd ... (PFS) in de lever dankzij de toevoeging ...
Breaking Medicine Technology:Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5
... , , SCOTTSDALE, Ariz., July 15 ... for many who fear Alzheimer,s disease . Now a ... New England Journal of Medicine suggests that the carriers of a common ... their mid-50s, far earlier than previously thought. , , ...
... , , , NEW YORK, ... today announced approximately $2.1 million in total funding to 10 research ... , Target validation is an essential ... to determine whether a molecule or mechanism of interest is a ...
Cached Medicine Technology:Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 2Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 3Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 4Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 5Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 6Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 7Michael J. Fox Foundation Awards Over $2 Million for Validation of 10 Parkinson's Therapeutic Targets 2Michael J. Fox Foundation Awards Over $2 Million for Validation of 10 Parkinson's Therapeutic Targets 3
(Date:7/7/2015)... (PRWEB) , ... July 07, ... ... a leading provider of unified communication management solutions, has announced the release ... Select. , This service pack includes a number of enhancements to the ...
(Date:7/7/2015)... ... July 07, 2015 , ... On May 29, 2015, ... and permits the use of gluten-free claims for gluten free oats and foods that ... the Gluten-Free Certification Program (GFCP) to include gluten-free oat products in Canada,” ...
(Date:7/7/2015)... ... July 07, 2015 , ... Connexion Point is holding an onsite job fair to hire ... 1769 Paragon Place, Suite 100, this upcoming Wednesday, July 8, and Thursday, July 9, from ... will be recruiting new applicants as well as holding onsite interviews. Interested parties are ...
(Date:7/7/2015)... ... July 07, 2015 , ... CSG ... have been selected by the Department of Vermont Health Access to provide Quality ... Information System (MMIS) and Integrated Contact Center System project. , Vermont is implementing ...
(Date:7/6/2015)... ... 06, 2015 , ... For over twenty years, Doctors on Liens ... Throughout the company’s history the goal has been to be a comprehensive network of ... And while Doctors on Liens has certainly achieved that goal, the addition of ...
Breaking Medicine News(10 mins):Health News:ISI Telemanagement Solutions, Inc. Releases Service Pack 5600 for Infortel® Select 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 4Health News:Connexion Point, a tech enabled healthcare services company, is holding on-site job fair July 8th and 9th to fill 400 positions at its new Memphis location 2Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 3
... that swimming helps immensely the children to stay hale ... ,Researches conducted over six years at the Jigalong, ... examined the impact on children's health where swimming pools ... Institute for Child Health Research study found that at ...
... Gum disease can do more than affecting just your ... disease and premature delivery. // The following is the ... at New York. ,Participants at the conference ... illness in association with gum disease. They further reflected ...
... tumor marker, elevated level of which is strongly suggestive ... by doctors to spot early signs of prostate cancer, // ... different criterion may be needed for establishment of prostate cancer ... age. ,The researchers from Duke University Medical Center ...
... the principle investigator said that the new technique of in ... molecules that can enhance or block different kinds of tastes.// ... growing mature taste receptor cells outside the body. They have ... prolonged period of time. This is a break through as ...
... Bradley Hasbro Children's Research Center (BHCRC) and Brown Medical ... said that // those who have high self-esteem and ... their asthma symptoms interfere with school. These children inspite ... facing asthma symptoms were associated with fewer school absences, ...
... of Preventive Medicine has weighed the impact of ... types of cessation help -nicotine // replacement therapy ... materials, cessation programs, telephone quit line, or web-based ... that television advertisements were extremely potent in carrying ...
Cached Medicine News:Health News:Unhealthy Gums Increase Risk Of Premature Delivery 2Health News:Functional Taste Cells Cultured In Vitro 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: